ORIGINAL RESEARCH article
Front. Public Health
Sec. Health Economics
Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1642895
This article is part of the Research TopicAdvancing Health Technology Assessment and Patient-Reported Outcomes: Innovations and Implications for Health Economics and Outcomes ResearchView all 5 articles
Quality of life and its contributors among patients with homozygous familial hypercholesterolemia in China
Provisionally accepted- 1Shanghai Health Development Research Center, Shanghai, China
- 2School of Public Administration, Hainan University, Hainan, China
- 3Department of Health Policy, School of Medicine, Stanford University, California, United States
- 4Shanghai Municipal Center for Health Promotion, Shanghai, China
- 5Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China
- 6School of Public Health, Fudan University, Shanghai, Shanghai Municipality, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: The aim of this study is to assess the quality of life of HoFH patients in China and to investigate the factors that influence quality of life. Methods: Data were obtained from a national epidemiological survey of HoFH patients conducted by Beijing Anzhen Hospital, affiliated with Capital Medical University, during 2017~2019. The questionnaire included patient demographic information, disease information, family economic status and health-related quality of life. Quality of life was assessed using the EuroQol five-dimension three-level questionnaire (EQ-5D-3L)EQ -5D-3L. Data processing and statistic tests are performed using Python libraries. Data cleaning and statistical analysis were performed using Python libraries including scipy and statsmodels.Results: This investigation incorporated a sample size of 53 patients diagnosed with HoFH, with an average age of 27.92 years. It was observed that 45.28% of these patients' families were subjected to catastrophic health expenditure. The mean and median health utility scores were calculated to be 0.849 and 0.875, respectively, a figure that is significantly lower when compared to the scores of the general population. Furthermore, it was noted that 52.83% of the patients exhibited some level of difficulty or extreme difficulty in at least one dimension of the EuroQol five-dimension three-level questionnaire (EQ-5D-3L). Significant Factors negatively affecting the quality of life of HoFH patients include the presence of atherosclerotic cardiovascular disease, hospitalization in the past year and taking multiple medications, higher than average healthcare expenditure per capita, catastrophic healthcare expenditure and debt due to HoFH. After application of Benjamini-Hochberg method to minimize type 1 error, the occurrence of atherosclerotic cardiovascular diseases(ASCVD) and debt due to HoFH are likely to exert the most significant influence. Substantial clinical relevance of the two factors are also evidenced by large effect sizes and adequate statistical power.Conclusions: Chinese patients with HoFH showed lower quality of life than the general population. Policy makers should consider the policy that improves early diagnosis, employment prospects, and the availability of HoFH-related interventions and provision of financial assistance for patients suffering from HoFH.
Keywords: China, Epidemiological survey, Homozygous familial hypercholesterolemia, Quality of Life, rare disease
Received: 07 Jun 2025; Accepted: 06 Aug 2025.
Copyright: © 2025 Tang, Ye, Zhang, He, Qi, Tang, Wang, Yang, Yang and HU. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yan Yang, Shanghai Health Development Research Center, Shanghai, China
Shanlian HU, School of Public Health, Fudan University, Shanghai, 200032, Shanghai Municipality, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.